{"id":36418,"date":"2013-05-16T23:13:31","date_gmt":"2013-05-17T03:13:31","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=36418"},"modified":"2013-05-18T22:41:39","modified_gmt":"2013-05-19T02:41:39","slug":"shame-5","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/05\/16\/shame-5\/","title":{"rendered":"shame…"},"content":{"rendered":"\n

<\/p>\n

This graphic is a cut down version of the flyer for the 4th KOL Relationship Summit<\/a> with just the session topics. It’s to help PHARMA types more effectively recruit and manage the physicians who they use to promote their products. As you read through these topics keep in mind that I didn’t make this up, it’s a real brochure for a real conference, even though it reads like a C.I.A. seminar for how to recruit and handle spy networks [and get around the Sunshine Act]. Each one is worse than the next. My opinion? State Medical Boards ought to make physicians participating in such things grounds for suspension of medical licenses. There’s nothing right about this. This isn’t what Hippocrates had in mind…<\/div>\n
\n
\n
4th KOL Relationship Summit<\/a><\/div>\n

Key Opinion Leaders (KOLs) possess a unique credibility, as their validity often stems from years of industry experience and medical affiliations. Relationship management is an essential part to a successful KOL program and helps foster a culture of transparent engagement and collaboration. As the healthcare landscape changes due to Healthcare Reform and the Sunshine Act, it is important for pharmaceutical, biotechnology, and medical device companies to know how their relationships with KOLs can be affected and what they must to do to maintain a valuable and engaging relationship.<\/strong><\/sup><\/p>\n

After three enormously successful events, ExL Pharma is excited to bring back the 4th KOL Relationship Summit. The goal of this conference is to offer professionals from pharmaceutical, medical device, and biotechnology companies a complete understanding of the issues and strategies for effectively engaging in valuable relationships with KOLs to drive the success of a drug or medical device, educate physicians, and maintain a balance with compliance and business objectives during a changing healthcare environment.<\/strong><\/sup><\/p>\n

By attending this conference, you will hear industry-specific case studies and examples including:<\/strong><\/sup><\/div>\n
    <\/p>\n
  • \n
    Adapting to the transparency of the Sunshine Act and the effect on KOL relationships<\/div>\n<\/li>\n
  • \n
    The role of medical affairs and KOL engagement<\/div>\n<\/li>\n
  • \n
    Defining the new wave of KOLs emerging from a changing healthcare environment<\/div>\n<\/li>\n
  • \n
    Leveraging local and global KOLs to stay ahead of industry globalization<\/div>\n<\/li>\n
  • \n
    Developing effective collaboration between commercial and medical departments<\/div>\n<\/li>\n
  • \n
    Maintain mutually beneficial KOL relationships<\/div>\n<\/li>\n
  • \n
    Understanding the thought leader perspective and expectations<\/div>\n<\/li>\n
  • \n
    Exploring the latest technologies for thought leader identification and expanded networking<\/div>\n<\/li>\n
  • \n
    Assisting KOLs in tracking and reporting payments<\/div>\n<\/li>\n
  • \n
    Developing a strategic KOL plan to align engagement with the product lifecycle<\/div>\n<\/li>\n

    <\/strong><\/sup><\/ul>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"

    This graphic is a cut down version of the flyer for the 4th KOL Relationship Summit with just the session topics. It’s to help PHARMA types more effectively recruit and manage the physicians who they use to promote their products. As you read through these topics keep in mind that I didn’t make this up, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-36418","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/36418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=36418"}],"version-history":[{"count":10,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/36418\/revisions"}],"predecessor-version":[{"id":36437,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/36418\/revisions\/36437"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=36418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=36418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=36418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}